SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.【JP:2395】Balance sheet
Market cap
¥64.4B
P/E ratio
18.1x
Provides drug development testing services to pharmaceutical companies and operates innovative intranasal drug delivery technology through spinout companies.
| 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Cash and cash equivalents | - | 7,276 | 4,918 | 7,419 | 5,313 | 5,142 | 5,250 | 7,231 | 6,629 | 10,533 | 10,275 | 12,032 |
| Marketable securities, current | - | - | 24 | 28 | - | - | - | 56 | 368 | - | 337 | - |
| Total cash & short-term investments | - | 7,276 | 4,942 | 7,447 | 5,313 | 5,142 | 5,250 | 7,287 | 6,997 | 10,533 | 10,611 | 12,032 |
| Accounts receivable, net | - | 3,127 | 3,107 | 2,843 | 2,556 | 1,987 | 2,605 | 2,954 | 3,502 | 4,760 | 5,779 | 6,643 |
| Total current assets | - | 19,011 | 16,306 | 18,146 | 15,290 | 11,666 | 12,410 | 14,780 | 16,134 | 23,900 | 30,838 | 32,940 |
| Property, plant and equipment, net | - | 19,543 | 19,894 | 17,105 | 14,654 | 13,687 | 13,700 | 12,898 | 13,156 | 18,879 | 26,358 | 34,833 |
| Marketable securities, non-current | - | 1,426 | 10,442 | 19,074 | 26,070 | 27,619 | 12,008 | 8,287 | 7,080 | 11,980 | 15,236 | 19,762 |
| Total non-current assets | - | 21,542 | 31,935 | 38,107 | 42,318 | 42,663 | 26,592 | 22,192 | 23,178 | 33,343 | 45,465 | 59,477 |
| Total assets | - | 40,552 | 48,241 | 56,253 | 57,608 | 54,329 | 39,002 | 36,972 | 39,313 | 57,242 | 76,302 | 92,417 |
| Accounts payable | - | - | - | - | - | - | - | - | - | 420 | 461 | 461 |
| Short-term debt | - | 10,680 | 10,316 | 11,558 | 11,524 | 11,348 | 5,998 | 3,487 | 2,943 | 8,923 | 7,826 | 11,778 |
| Long-term debt, current | - | 6,007 | 5,886 | 5,579 | 4,469 | 3,307 | 3,872 | 3,365 | 2,800 | 4,790 | 7,600 | 8,665 |
| Total current liabilities | - | 19,325 | 19,496 | 19,676 | 20,003 | 17,768 | 12,951 | 11,916 | 13,374 | 21,012 | 23,568 | 29,256 |
| Total non-current liabilities | - | 11,583 | 12,270 | 14,104 | 11,390 | 8,084 | 9,669 | 9,218 | 6,216 | 9,871 | 18,574 | 23,075 |
| Total liabilities | - | 30,908 | 31,766 | 33,780 | 31,393 | 25,851 | 22,620 | 21,134 | 19,590 | 30,883 | 42,142 | 52,331 |
| Retained earnings | - | -7,587 | -7,332 | -8,260 | -12,059 | -10,083 | -2,489 | 3,854 | 10,196 | 13,766 | 17,216 | 20,088 |
| Stockholders' equity | 10,515 | 9,644 | 16,475 | 22,473 | 26,216 | 28,478 | 16,382 | 15,839 | 19,723 | 26,359 | 34,161 | 40,086 |